AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS

Ahmed Almradi  ¹     Christopher Ma  ¹     Geert R. D'Haens  ¹     William Sandborn  ¹     Claire Parker  ¹     Leonardo Guizzetti  ¹     Paula Borralho Nunes  ²     Geert De Hertogh  ³     Roger Feakins  ⁴     Reena Khanna  ⁵     Gregory Y. Lauwers  ⁶     Aart Mookhoek  ⁷     Reet Pai  ⁸     Laurent Peyrin-Biroulet  ⁹     Robert Riddell  ¹⁰     Christophe Rosty  ¹¹     David F. Schaeffer  ¹²     Mark Valasek  ¹³     Brian G. Feagan  ¹³     Vipul Jairath  ¹³     Rish Pai  ^14    
1 Robarts Clinical Trials Inc., London, Canada
² Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
³ KU Leuven, Leuven, Belgium
⁴ Royal Free London NHS Trust, London, United Kingdom
⁵ University of Western Ontario, London, Canada
⁶ Moffitt Cancer Center, Tampa, United States
⁷ VU University Medical Centre, Amsterdam, Netherlands
⁸ University of Pittsburgh School of Medicine, Pittsburgh, United States
⁹ Nancy University Hospital, Vandoeuvre les Nancy, France
¹⁰ Mount Sinai Hospital, University of Toronto, Toronto, Canada
¹¹ The University of Melbourne, Parville, Australia
¹² University of British Columbia, Vancouver, Canada
¹³ University of California San Diego, La Jolla, United States
¹⁴ Mayo Clinic, Scottsdale, United States

Session
IBD Clinical III

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)